SCHEMBL29403054

SCHEMBL29403054

FC(F)c1nnc(-c2ccc(Cn3cnc(-c4ccccc4)c3)nc2)o1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 15/20 0.63
▸ HDAC1 Q13547 4/20 0.49
▸ HPGDS O60760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24216493 1.00 HDAC6 (0.63) HDAC6HDAC1HPGDS
SCHEMBL25247874 0.89 HDAC6 (0.53) HDAC6HDAC1
SCHEMBL25208787 0.88 HDAC6 (0.51) HDAC6HDAC1
SCHEMBL30425036 0.88 HDAC6 (0.51) HDAC6HDAC1
SCHEMBL26227434 0.88 HDAC6 (0.51) HDAC6HDAC1
SCHEMBL25217344 0.86 HDAC6 (0.52) HDAC6HDAC1
SCHEMBL25258116 0.85 HDAC6 (0.48) HDAC6HDAC1
SCHEMBL29398947 0.84 HDAC6 (0.67) HDAC6HDAC1
SCHEMBL24216054 0.84 HDAC6 (0.67) HDAC6HDAC1
SCHEMBL24216351 0.84 HDAC6 (0.55) HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 — — CN claimed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 — — CN claimed
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 — — CN disclosed
US-12202823-B2 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors QUIMATRYX, S.L. (ES) 2025-01-21 — — US disclosed
EP-4185586-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2023-05-31 — — EP disclosed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 — — CN disclosed
CN-116133658-A Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same 株式会社 钟根堂 2023-05-16 — — CN disclosed
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS FUNDACIÓN KERTOR (ES) 2022-07-07 — — US disclosed
EP-3956324-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS QUIMATRYX, S.L. (ES) 2022-02-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC6, HDAC1, HDAC3 HDAC6 1/4885HDAC1 2/4885HPGDS 1258/4885
US-12202823-B2 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors HDAC6, HDAC1, HDAC3 HDAC6 1/4885HDAC1 2/4885HPGDS 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback